1
|
Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion. Exp Hematol Oncol 2024; 13:34. [PMID: 38528594 DOI: 10.1186/s40164-024-00499-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 03/08/2024] [Indexed: 03/27/2024] Open
Abstract
BACKGROUND Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhibitor. METHODS A panel of nine MCL cell lines were used for in vitro experiments. Four patient derived xenografts (PDX) obtained from patients with chemotherapy and ibrutinib-refractory MCL were used for in vivo proof-of-concept studies. Changes of the mitochondrial membrane potential, energy-metabolic pathways, AKT activity, and pro-apoptotic priming of MCL cells were evaluated by JC-1 staining, Seahorse XF analyser, genetically encoded fluorescent AKT reporter, and BH3 profiling, respectively. MCL clones with gene knockout or transgenic (over)expression of CDKN2A, MYC, CDK4, and RB1 were used to estimate impact of these aberrations on sensitivity to palbociclib, and venetoclax. RESULTS Co-targeting MCL cells with palbociclib and venetoclax induced cytotoxic synergy in vitro and in vivo. Molecular mechanisms responsible for the observed synthetic lethality comprised palbociclib-mediated downregulation of anti-apoptotic MCL1, increased levels of proapoptotic BIM bound on both BCL2, and BCL-XL and increased pro-apoptotic priming of MCL cells mediated by BCL2-independent mechanisms, predominantly palbociclib-triggered metabolic and mitochondrial stress. Loss of RB1 resulted in palbociclib resistance, while deletion of CDKN2A or overexpression of CDK4, and MYC genes did not change sensitivity to palbociclib. CONCLUSIONS Our data strongly support investigation of the chemotherapy-free palbociclib and venetoclax combination as an innovative treatment strategy for post-ibrutinib MCL patients without RB1 deletion.
Collapse
Affiliation(s)
- Diana Malarikova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic
| | - Radek Jorda
- Department of Experimental Biology, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic
| | - Kristyna Kupcova
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic
- BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jana Senavova
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic
- BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Alexandra Dolnikova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Eva Pokorna
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Dmitry Kazantsev
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Kristina Nozickova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Dana Sovilj
- Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic
| | - Celine Bellanger
- Integrated Research Center in Immunology and Oncology, CRCI2NA, Nantes University, Nantes, France
| | - David Chiron
- Integrated Research Center in Immunology and Oncology, CRCI2NA, Nantes University, Nantes, France
| | - Ladislav Andera
- BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic
- Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic
- Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
| | - Vladimir Krystof
- Department of Experimental Biology, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic
| | - Miroslav Strnad
- Laboratory of Growth Regulators, Palacky University Olomouc and Institute of Experimental Botany, The Czech Academy of Sciences, Olomouc, Czech Republic
| | - Karel Helman
- Faculty of Informatics and Statistics, Prague University of Economics and Business, Prague, Czech Republic
| | - Magdalena Klanova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic
| | - Marek Trneny
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic
| | - Ondrej Havranek
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic
- BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Pavel Klener
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.
| |
Collapse
|
2
|
Skrlova E, Uherkova E, Klimova A, Malarikova D, Svozilkova P, Matous P, Herynek V, Kucera T, Klener P, Heissigerova J. Experimental model of primary intraocular lymphoma based on BALB/CaNn strain and A20 cells is optimal for investigational research. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2024. [PMID: 38410917 DOI: 10.5507/bp.2024.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2024] Open
Abstract
AIM The purpose of this project was to compare the characteristics of two experimental murine models of primary intraocular lymphoma (PIOL) and determine which experimental model is most suitable for further investigational research to elucidate the pathophysiology of PIOL and to find new therapeutical strategies. METHODS In both experimental models PIOL was induced in immunocompetent mice with intravitreal injection of syngeneic B-cell lymphoma cell lines. Murine strain C3H/HeN and cell line 38C13 were used in the first model and BALB/CaNn mice and cell line A20 in the second model. During the experiments, thorough clinical evaluation (using photo documentation, ultrasonography, and MRI) and histological evaluation were performed. RESULTS In both models, the percentage of PIOL development was high, reaching nearly 80%. Disease progression was faster in C3H/HeN with exophthalmos occurring on average on day 10. Vitreous involvement was a predominant sign in the clinical presentation of this group. In BALB/CaNn mice exophthalmos occurred on average on day 22. The predominant clinical sign in the BALB/CaNn group was tumorous infiltration of the retina, optic disc, and tumorous retinal detachment. CONCLUSION Slower progression of the disease in BALB/CaNn mice, greater possibility to examine the retina due to mild vitreous involvement, and later occurrence of exophthalmos makes this strain more suitable for further investigational research.
Collapse
Affiliation(s)
- Eva Skrlova
- Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - Eva Uherkova
- Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - Aneta Klimova
- Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - Diana Malarikova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Czech Republic
- 1st Department of Medicine, Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - Petra Svozilkova
- Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - Petr Matous
- Centre for Advanced Preclinical Imaging, First Faculty of Medicine, Charles University, Czech Republic
| | - Vit Herynek
- Centre for Advanced Preclinical Imaging, First Faculty of Medicine, Charles University, Czech Republic
| | - Tomas Kucera
- Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Czech Republic
| | - Pavel Klener
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Czech Republic
- 1st Department of Medicine, Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - Jarmila Heissigerova
- Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| |
Collapse
|
3
|
Obr A, Benesova K, Janikova A, Mocikova H, Belada D, Hruskova A, Vockova P, Salek D, Sykorova A, Furst T, Malarikova D, Papajik T, Trneny M, Klener P. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. Ann Hematol 2023; 102:107-115. [PMID: 36369497 PMCID: PMC9807478 DOI: 10.1007/s00277-022-05023-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Accepted: 10/19/2022] [Indexed: 11/12/2022]
Abstract
Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of 14.0 months, 56 patients relapsed/progressed, and 45 died. The overall response rate was 66%, with 31% of complete metabolic remissions on PET/CT. The median progression-free and overall survival (OS) rates were 10.3 and 23.1 months, respectively. The median OS from ibrutinib failure was 3.7 months. High proliferation rate by Ki67 (≥ 30%) and two or more previous therapy lines both negatively correlated with outcome (HR = 2.2, p = 0.04, and HR = 2.06, p = 0.08, respectively). Female gender borderline correlated with better outcome (HR = 0.53, p = 0.08). In multivariate analysis, Ki67 and response to ibrutinib both correlated with OS (p < 0.05). Importantly, ibrutinib appeared to better control nodal and extranodal lymphoma than bone marrow (BM) involvement. From 20 patients with detectable BM infiltration (before ibrutinib initiation) achieving complete (n = 13) or partial (n = 7) metabolic remission, none achieved remission in BM. We confirmed good efficacy of ibrutinib in unselected heavily pre-treated MCL patients. Our findings support the use of a combination of ibrutinib and rituximab in patients with BM involvement.
Collapse
Affiliation(s)
- Ales Obr
- Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Katerina Benesova
- First Department of Internal Medicine–Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808 Czech Republic
| | - Andrea Janikova
- Department of Haematology and Oncology, University Hospital, Brno, Czech Republic
| | - Heidi Mocikova
- Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - David Belada
- 4th Department of Internal Medicine–Haematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Andrea Hruskova
- Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Petra Vockova
- First Department of Internal Medicine–Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808 Czech Republic
| | - David Salek
- Department of Haematology and Oncology, University Hospital, Brno, Czech Republic
| | - Alice Sykorova
- 4th Department of Internal Medicine–Haematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Tomas Furst
- Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic
| | - Diana Malarikova
- First Department of Internal Medicine–Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808 Czech Republic
| | - Tomas Papajik
- Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Marek Trneny
- First Department of Internal Medicine–Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808 Czech Republic
| | - Pavel Klener
- First Department of Internal Medicine–Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808 Czech Republic ,Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
4
|
Skrlova E, Uherkova E, Malarikova D, Klimova A, Svozilkova P, Kesa P, Matous P, Herynek V, Kucera T, Klener P, Heissigerova J. Comparison of two primary intraocular lymphoma experimental murine models. Acta Ophthalmol 2022. [DOI: 10.1111/j.1755-3768.2022.0158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- Eva Skrlova
- First Faculty of Medicine, Department of Ophthalmology Charles University and General University Hospital in Prague Prague 2 Czech Republic
| | - Eva Uherkova
- First Faculty of Medicine, Department of Ophthalmology Charles University and General University Hospital in Prague Prague 2 Czech Republic
| | - Diana Malarikova
- First Faculty of Medicine, 1st Department of Medicine, Department of Haematology Charles University and General University Hospital in Prague Prague 2 Czech Republic
- First Faculty of Medicine, Institute of Pathological Physiology Charles University Prague 2 Czech Republic
| | - Aneta Klimova
- First Faculty of Medicine, Department of Ophthalmology Charles University and General University Hospital in Prague Prague 2 Czech Republic
| | - Petra Svozilkova
- First Faculty of Medicine, Department of Ophthalmology Charles University and General University Hospital in Prague Prague 2 Czech Republic
| | - Peter Kesa
- First Faculty of Medicine Charles University, Centre for Advanced Preclinical Imaging Prague 2 Czech Republic
| | - Petr Matous
- First Faculty of Medicine Charles University, Centre for Advanced Preclinical Imaging Prague 2 Czech Republic
| | - Vit Herynek
- First Faculty of Medicine Charles University, Centre for Advanced Preclinical Imaging Prague 2 Czech Republic
| | - Tomas Kucera
- First Faculty of Medicine, Institute of Histology and Embryology Charles University Prague 2 Czech Republic
| | - Pavel Klener
- First Faculty of Medicine, 1st Department of Medicine, Department of Haematology Charles University and General University Hospital in Prague Prague 2 Czech Republic
- First Faculty of Medicine, Institute of Pathological Physiology Charles University Prague 2 Czech Republic
| | - Jarmila Heissigerova
- First Faculty of Medicine, Department of Ophthalmology Charles University and General University Hospital in Prague Prague 2 Czech Republic
| |
Collapse
|
5
|
Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, Jirkuvova A, Petrackova A, Malarikova D, Forsterova K, Cudova B, Sedlarikova L, Berkova A, Kasalova N, Papajik T, Trneny M. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol 2020; 191:e103-e106. [PMID: 32862455 DOI: 10.1111/bjh.17063] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Ales Obr
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Pavel Klener
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.,Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Tomas Furst
- Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic
| | - Eva Kriegova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Zuzana Zemanova
- Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic
| | - Helena Urbankova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Andrea Jirkuvova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Anna Petrackova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Diana Malarikova
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.,Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Kristina Forsterova
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Barbora Cudova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Lenka Sedlarikova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Adela Berkova
- Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Prague, Czech Republic
| | - Nela Kasalova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Tomas Papajik
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - Marek Trneny
- First Department of Medicine - Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|